128 PART THREE | DELIRIUM Table 1. Baseline characteristics (intention-to-treat population. Olanzapine (n= 49) Haloperidol (n= 49) Mean age, years (SD) 69.9 (9.3) 68.4 (11.9) Sex, No. (%) Male 33 (67) 35 (71) Female 16 (33) 14 (29) DRS-R-98 Severity score, mean (SD) 18.1 (3.8) 17.6 (3.4) Total score, mean (SD) 23.5 (3.9) 23.1 (3.4) Delirium subtype, No. (%) Hyperactive 16 (33) 20 (41) Hypoactive 10 (20) 17 (35) Mixed 21 (43) 12 (24) Unspecified 2 (4) - Use of opioids, No. (%) 33 (67) 35 (71) Use of benzodiazepines, No. (%) 18 (37) 21 (43) Use of neuropathic pain medication, No. (%) 7 (14) 11 (22) Use of psychotropic medication, No. (%) 3 (6) 4 (8) Precipitating factorsa, Median No. (IQR; range) 2 (1-3; 0-5) 2 (1-3; 0-5) Admission type, No. (%) Hospital 45 (92) 43 (88) Hospice 4 (8) 6 (12) Reason for admission, No. (%) Emergency 41 (84) 42 (86) Scheduled 8 (16) 7 (14) Abbreviations: DRS-R-98, Delirium rating scale revised 98; IQR, interquartile range; SD, standard deviation aPrecipitating factors included: change in dose or type of opioids (<48 hours before diagnosis of delirium); dehydration; infection; intracranial malignancy; infection; metabolic imbalances. Efficacy Median olanzapine dose was 8.8 mg (IQR, 5.0-15.0 mg) on day 1, 5.0 mg (IQR, 0.0-10.0 mg) on day 2, and 5.0 mg (IQR, 1.9-10.0 mg) at the end of study. For haloperidol, median dose was 2.5 mg (IQR, 1.0-4.8 mg) on day 1, 1.3 mg (IQR, 0.5-2.9 mg) on day 2, and 1.8 mg (IQR, 0.5-2.8 mg) at the end of study. In the ITT cohort, DRR was 45% (95% CI, 31-59) for olanzapine, and 57% (95% CI, 43-71) for haloperidol (ΔDRR-12%; odds ratio [OR], 0.61; 95% CI, 0.2-1.4]; p= .23). DRR was 56% for olanzapine (95% CI, 41-72), and 68% (95% CI 54-83) for haloperidol (ΔDRR-12%; OR, 0.61; 95% CI, 0.2-1.5; p= .27) in the PP cohort. Mean TTR in the olanzapine arm was 4.5 days (95% CI, 3.2-5.9), and it was 2.8 days (95% CI, 1.9-3.7; p= .18) in the haloperidol arm.
RkJQdWJsaXNoZXIy MjY0ODMw